Study shows progress with stem cell alternative
New York: Scientists reported more progress today with a method of creating stem cells without using embryos.
The advance in cell reprogramming by researchers in Boston was praised as a more efficient way of turning skin cells into stem cells, a step toward developing new medical treatments. One expert said the new approach might be the first practical way to make such cells for creating new tissue to treat conditions like diabetes and Parkinson`s disease.
In 2007, when scientists first reported they had reprogrammed skin cells into stem cells, it was hailed as an alternative to getting stem cells from embryos, which are then destroyed.
Since then, researchers have been working on fine-tuning the method.
Embryonic stem cells, which have the ability to morph into any type of cell, continue to be controversial. Last month, a US judge cut off federal funding for research with them. (A different court ruled Tuesday that funding could resume while legal arguments proceed.)
The reprogramming produces what scientists call iPS cells, for induced pluripotent stem cells. The technology first used to make them involved disrupting the DNA of the skin cells. That method would introduce a risk of cancer to any patient who got transplanted tissue derived from the iPS cells. So researchers have been developing alternate methods.
The new approach is more efficient than earlier efforts and avoids tampering with DNA, said Derrick Rossi of Children`s Hospital Boston and the Harvard Stem Cell Institute. He and his colleagues reported the work in a paper published online today by the journal Cell Stem Cell.
Their technique treats skin cells with modified forms of RNA, a chemical cousin of DNA that normally transmits instructions from genes to the protein-making machinery of the cell. Rossi has patented the technique and formed a company to use it.
Experts unconnected with the study praised the work. The method appears to be highly efficient, which implies the resulting iPS cells will be of good quality, said Marius Wernig, an iPS researcher at Stanford University.
It will take further work to see if the initial promise is borne out, Wernig said. If so, it would be the first practical method for generating iPS cells that could be used for transplant therapies, he said.